Goji Berries & Energy Expenditure

Status Completed

Clinical Trial Summary

Effects of foods or food substances on energy expenditure are of particular interest, because of the increasing prevalence of obesity and its consequent metabolic diseases like type II diabetes and fatty liver disease, all risk factors for the development of cardiovascular diseases (CVDs). Recently, the Goji berry (Lycium Barbarum, wolfberry) was introduced into the Western diet. L. Barbarum originates from Asia, where it is used to improve the health of several organs. Although L. Barbarum is promoted as a super food with many beneficial effects, consistent scientific evidence for these effects is lacking. In one study, it was found that short-term intake of L. Barbarum polysaccharides - equal to 150 g of fresh berries - increased postprandial oxygen consumption. This indicates that L. Barbarum might exert beneficial effects on energy expenditure. Furthermore, long-term intervention trials have shown beneficial effects of L. Barbarum on lipid and glucose metabolism in mice and type II diabetic patients and on inflammatory status in healthy elderly. Altogether, L. Barbarum has the potential to be used as a functional food to increase metabolic health, but detailed information on the postprandial effects of L. Barbarum is missing. We therefore propose this double-blinded, randomized, placebo controlled intervention trial to investigate the effect of a single dose of L. Barbarum on postprandial energy expenditure substrate oxidation, metabolic flexibility, lipid and glucose metabolism and inflammatory markers.

Clinical Trial Description

Objectives:

The primary objective of this study is to investigate the effect of a single dose of L. Barbarum on postprandial energy expenditure. Secondary objectives are to investigate the effect of a single dose of L. Barbarum on postprandial lipid and carbohydrate oxidation and metabolic flexibility, on postprandial lipid and glucose metabolism and on inflammatory markers.

Study design:

This is a double blind, randomized, placebo-controlled intervention trial with two test days separated by a washout period of at least 1 week.

Study population:

The study population will consist of 20 apparently healthy overweight (BMI between 25 and 30 kg/m2) men aged 18-65 years.

Intervention:

All subjects will receive a mixed meal including 25 grams of dried L. Barbarum as the intervention product and a matched mixed meal without L. Barbarum as the placebo product. The meals will be matched for energy content and macronutrient composition. ;

Study Design

Related Conditions & MeSH terms

Overweight

Clinical Trial Details

NCT number	NCT02779985
Study type	Interventional
Source	Maastricht University Medical Center
Contact
Status	Completed
Phase	N/A
Start date	April 2016
Completion date	December 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04507867` - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III	N/A
Terminated	`NCT03299881` - Safety and Effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS)-Assisted Weight Loss	N/A
Completed	`NCT02805478` - Fat-Associated Cardiovascular Organ Dysfunction
Active, not recruiting	`NCT02558920` - Meta-analyses of Food Sources of Fructose-Containing Sugars and Obesity
Completed	`NCT03759743` - Evaluate the Efficacy and Safety of LMT1-48 on Reducing Body Fat in Overweight Subject	N/A
Completed	`NCT03610958` - Safety and Performance Evaluation of the Epitomee Device for Enhancing Satiety and Weight Loss.	N/A
Completed	`NCT03678766` - CHARGE: Controlling Hunger and ReGulating Eating	N/A
Completed	`NCT04430465` - Effects of Wholegrains on Children's Health (KORN)	N/A
Completed	`NCT04117802` - Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome	N/A
Completed	`NCT05376865` - Effects of Vitamin D Supplementation on Obesity, Inflammatory and Metabolic Markers	N/A
Completed	`NCT03625427` - Effect of Palmitoleic Acid on C-reactive Protein	N/A
Active, not recruiting	`NCT03435445` - Online Platform for Healthy Weight Loss (POEmaS)	N/A
Enrolling by invitation	`NCT05576116` - Combined Bariatric Surgery and Pancreas After Kidney Transplantation for Type II Diabetics	N/A
Recruiting	`NCT05249465` - Spark: Finding the Optimal Tracking Strategy for Weight Loss in a Digital Health Intervention	N/A
Active, not recruiting	`NCT06023095` - A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities	Phase 1
Completed	`NCT03648892` - Brain Dopamine Function in Human Obesity	Early Phase 1
Not yet recruiting	`NCT05751993` - Piloting a Reinforcement Learning Tool for Individually Tailoring Just-in-time Adaptive Interventions	N/A
Recruiting	`NCT02887950` - Resistant Starch, Epigallocatechin Gallate and Chlorogenic Acid for Body Weight Loss in Menopause	N/A
Completed	`NCT03097237` - High Fiber Rye Foods for Weight and Body Fat Reduction	N/A
Terminated	`NCT02796144` - MEtformin and Lorcaserin for WeighT Loss in Schizophrenia	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Goji Berries and Energy Expenditure

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms